. (2023). Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care. Diabetes Obes Metab. http://doi.org/10.1111/dom.14985
I. Idris
First name
I.
Last name
Idris
. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437
. (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799
. (2018). Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2018-000512
. (2018). The Trend of High-Dose Insulin Usage Among Patients with Diabetes in the UK: A Retrospective Study. Diabetes Ther. http://doi.org/10.1007/s13300-018-0515-0
. (2021). Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK. Diabetes Obes Metab. http://doi.org/10.1111/dom.14580